Perspective: Speculative role of Tmp21 mediated protein secretory pathway during endoplasmic reticulum (ER) stress induced chronic inflammation

By deploying myelofibrosis as the disease context, I wish to propose that increased availability of Tmp21 (an NFAT gene target) induces aberrant protein secretion from the ER contributing to pathological consequences, which has not been elucidated before. Primary myelofibrosis is now mainly considered as an advanced stage of BCR-ABL1 negative myeloproliferative neoplasms (MPN), which otherwise include polycythemia vera and essential thrombocythemia. Myelofibrosis is defined by an increased insoluble collagen fiber deposition in the bone marrow2 and harbors chronic inflammation as an important component in disease progression.

💡 Research Summary

The manuscript puts forward a speculative but mechanistically grounded hypothesis that the p24 family member Tmp21, a transcriptional target of NFAT, plays a pivotal role in linking endoplasmic reticulum (ER) stress to chronic inflammation in primary myelofibrosis (PMF). By positioning PMF as a prototypical BCR‑ABL1‑negative myeloproliferative neoplasm (MPN) characterized by excessive insoluble collagen deposition and a persistent inflammatory milieu, the authors create a disease context in which dysregulated protein trafficking can have profound pathological consequences.

First, the paper reviews the canonical functions of Tmp21 in COPI/COPII‑mediated transport between the ER and Golgi apparatus. Under normal conditions Tmp21 contributes to quality‑controlled cargo selection, ensuring that only properly folded proteins proceed to the secretory pathway. The authors then integrate recent data showing that NFAT, a transcription factor activated by chronic cytokine signaling in MPNs, directly up‑regulates Tmp21 expression. In PMF, sustained NFAT activity is driven by elevated IL‑6, TNF‑α, and other inflammatory mediators, creating a feed‑forward loop that boosts Tmp21 levels.

Second, the manuscript links heightened Tmp21 to an “overloaded” ER environment. Persistent ER stress triggers the unfolded protein response (UPR) via PERK‑eIF2α, IRE1α‑XBP1, and ATF6 pathways. When Tmp21 is overabundant, the conventional COPI/COPII vesicular system becomes saturated, leading to the formation of atypical, Tmp21‑rich transport vesicles that bypass the usual quality‑control checkpoints. These vesicles can release partially folded or misfolded proteins into the extracellular space, a process the authors term “non‑canonical secretion.”

Third, the authors argue that non‑canonical secretion has two major pathological outputs in PMF. (1) Fibroblast activation: aberrant delivery of collagen precursors, TGF‑β, PDGF, and other matrix‑modulating proteins directly stimulates marrow fibroblasts, accelerating the deposition of insoluble collagen fibers that define myelofibrosis. (2) Immune amplification: extracellular misfolded proteins act as danger‑associated molecular patterns (DAMPs), further stimulating dendritic cells and macrophages to produce IL‑1β, IL‑6, and TNF‑α, thereby reinforcing NFAT activation and sustaining the inflammatory loop.

The paper contrasts this Tmp21‑driven axis with the well‑studied JAK2‑V617F and CALR mutations that dominate current MPN therapeutics. While JAK inhibitors such as ruxolitinib blunt cytokine signaling, they do not address the upstream ER stress or the aberrant secretory pathway. Consequently, the authors propose several therapeutic strategies aimed at Tmp21: (i) RNA‑based knockdown (siRNA or antisense oligonucleotides) to reduce Tmp21 transcription; (ii) small‑molecule inhibitors that disrupt Tmp21‑p24 complex formation or its interaction with COPI/COPII coats; (iii) indirect NFAT inhibition using calcineurin blockers (e.g., cyclosporine A) to lower Tmp21 transcription. They caution, however, that Tmp21 is essential for normal protein trafficking, so any intervention must achieve selective modulation rather than complete ablation to avoid cytotoxicity.

Finally, the manuscript outlines a roadmap for experimental validation. Suggested studies include generating a transgenic mouse with hematopoietic‑specific Tmp21 overexpression to assess collagen deposition and cytokine profiles, and employing CRISPR‑mediated Tmp21 knock‑down in primary PMF patient‑derived fibroblasts to test reversal of fibrotic phenotypes. The authors also advocate for proteomic analyses of extracellular vesicles from PMF marrow cultures to detect signatures of non‑canonical secretion.

In summary, the paper posits that Tmp21 acts as a molecular bridge between ER stress and chronic inflammation, driving the fibrotic and cytokine‑rich environment of primary myelofibrosis. By highlighting this previously underappreciated pathway, the authors open new avenues for therapeutic intervention that complement existing JAK‑targeted strategies and may ultimately improve outcomes for patients with advanced MPNs.